Diabesity: A Multidisciplinary Approach E-Book
54,90 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
Diabesity: A Multidisciplinary Approach Diabesity refers to the linkageof both diabetes and obesity that results in the coexistence of these 2conditions. Research has identified pathophysiological mechanisms revolvingaround insulin resistance and hyperinsulinemia. Diabesity has importantdiagnostic and therapeutic implications. This book is a multidisciplinaryreview of diabesity. It highlights the various pharmacological methods ofmanaging the condition. The book presents 10 chapterscontributed by more than 40 experts from around the world. The review startswith an overview of diabesity and progressively describes the relationships ofdiabesity with the choice of diets and psychological factors. The chapters thencover the role of adipokines as therapeutic biomarkers before presentingresearch on medicinal and nutritional approaches to treat the condition.Modern approaches to diabesitytreatment such as the use of new bioactive phytochemicals, mitigatingmeta-inflammation and laboratory techniques are also reviewed in the book. Diabesity: A MultidisciplinaryApproach is a timelyreference for clinicians (in endocrinology and family medicine subspecialties)and students of pharmacology and medicinal chemistry on the intricaterelationship between diabetes and obesity.
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 433
Veröffentlichungsjahr: 2001
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
PREFACE
Diabesity is a recently coined term that encompasses two closely related concepts, obesity and diabetes. It is currently a worldwide epidemic, both in industrialized and developing countries, with devastating consequences in terms of life, social and economic costs.
Strategies for the prevention and treatment of obesity and insulin resistance are mainly associated to lifestyle modifications, including healthy hypocaloric dietary treatments and the increase in physical activity.
The important role played by the acquisition of certain eating patterns from childhood onwards and how these are influenced by psychological factors in the adulthood is becoming evident. In this book, we will focus on the emotional mechanisms behind food choices and their importance for the acquisition of individual eating patterns.
Dietary interventions aim to reduce body weight and fat mass in order to reduce obesity and related pathologies as diabetes regarding insulin resistance. The dietary guidelines differ between countries and the book discusses them, highlighting their similarities and differences. In this context, the concept of sustainable diet has recently emerged, referring to those diets protective and respectful of ecosystems, safe and healthy, that optimize natural resources.
Moreover, meta-inflammation is among the mechanisms that link obesity and type 2 diabetes. It is characterized by a chronic, low-grade inflammation, with relatively high levels of pro-inflammatory cytokines as IL-6 or TNF-α, associated with a metabolic implication of adipose tissue. Regarding inflammation and its downregulation by dietary patterns, the Mediterranean Diet is characterized by low intake of meat (especially red meat), refined grains, and saturated fats, and is mainly based on the intake of whole cereals, legumes, fruit and vegetables, providing bioactive compounds able to modulate stress-response pathways, upregulating antioxidant enzymes.
The book also shows the potential of some medicinal plants with antidiabetic properties, as Helianthus tuberosus and Momordica charantia, rich in inulin and insulin-like peptides, respectively, which are responsible for their effect on glucose control. The main families of phytochemical compounds with a proven beneficial role against diabesity are described, including flavonoids, phenolic acids, xanthines, and triterpenes, among others. The combined consumption of all of them can enhance their action at different levels and this consumption occurs preferably through food, in reduced amounts over the years.
Moreover, the study of the microbiota is studied in another chapter. Obesity and type 2 diabetes are associated with changes in the intestinal microbiota (dysbiosis), leading to metabolic alterations in plasmatic lipids and glucose. In particular, changes in the Firmicutes to Bacterioidetes ratio have been considered as a marker for obesity complications, as well as the reduced diversity of microbiota populations. Gut microbiota is a novel target for the management of diabesity and dietary interventions are generally accompanied by changes in microbiota composition and metabolic improvements.
Management and study of factors involved in the physiopathology of Diabesity require the use of robust and sensitive techniques, including metabolomics, genomics and microbiome analysis. The latest advances in the techonologies and laboratory equipment are critically assessed. The last chapter summarizes the new strategies aimed to fight against Diabesity, from a holistic approach. This includes actions based on the latest research in psychology on the factors that influence food choices. New advances in the Pharmacology area are reviewed, as this approach becomes crucial when nutritional of physical activity regimes have failed.
We owe special thanks to all the authors for their valuable chapters that have made possible the publication of this book. We also thank the editorial staff of Bentham Science for their assistance and support.
List of Contributors
Diabesity: Obesity And Type II Diabetes As A Real Health Problem In Developed Countries
Karina Ramírez-Alarcón1,Ana Maria Labraña1,Montserrat Victoriano1,Lorena Meléndez-Illanes1,Miquel Martorell1,*Abstract
is a multifactor disease resulting from the interaction of multiple genetic and environmental factors, such as sedentary lifestyle and the diet of the individual. On the other hand, diabetes mellitus is a complex metabolic disease that involves multiple organ systems, and it is characterized by chronic hyperglycemia due to a defect in the glycemic regulation as a result of insulin secretion, its actions or both. Combined, these diseases provide the concept of diabesity, which is defined as the alloy of type II diabetes and obesity, with or without associated risk factors. Obesity encourages diabetes, and both diseases are considered two global epidemics of the modern age that show no signs of decreasing their prevalence and contribute to cardiovascular diseases, the leading cause of death worldwide. This chapter is aimed to characterize both physiopathology and impact on health to understand their management and treatment.
INTRODUCTION
Diabesity is defined as the combination of type II diabetes mellitus (T2DM) and obesity, with or without risk factors associated with dyslipidemia and hypertension [1]. Obesity feeds diabetes and both diseases are considered two modern twin epidemics that show no signs of decreasing their prevalence and contribute to cardiovascular disease, the leading cause of death worldwide [2]. Decades ago, these common non-communicable diseases were linked to developed countries but currently are now common in developing countries.
Obesity is defined by the World Health Organization (WHO) as an abnormal or excessive accumulation of fat that presents a risk factor for health [3]. Body mass
index (BMI) (kg/m2) is a raw value determining obesity. In adults, a person with a BMI ≥ 30 kg/m2 is considered obese and a person between the previous value and ≥ 25 kg/m2 is considered overweight.
Diabetes mellitus, also known simply as diabetes, is a serious, chronic, and complex metabolic disorder with multiple etiologies and profound chronic and acute consequences [4]. Diabetes is a public health issue in both developed and developing countries, which implies a significant socioeconomic challenge worldwide. Diabetes is a multifactorial disease in which genetic and environmental factors contribute significantly to its development. During the development of diabetes, the body is unable to adequately metabolize sugar because insulin acts poorly in the tissues due to insensitivity or deficiency of it. Insulin is an anabolic peptide hormone that regulates the metabolism of sugar in the blood. Its structure is presented in Fig. (1).
Fig. (1)) Primary structure of human insulin.The inability of insulin to regulate blood sugar occurs when the pancreas produces not enough insulin or when the organism is unable to effectively use the insulin produced. The physiological response to this situation is that the organism decomposes its own macromolecules, fat, proteins, and glycogen to produce glucose. This leads to high levels of blood glucose and excess production of ketonic bodies in the liver [5, 6].
There are several types of insulin misbalance described, type 1 diabetes mellitus (T1DM) and T2DM being the best known and studied (Fig. 2). T1DM is known as insulin-dependent diabetes and is mainly due to the destruction of the pancreatic beta islets, which leads to poor insulin production [7]. Patients with T1DM are prone to a ketoacidosis situation and need the daily administration of insulin to control their blood glucose levels. They need the exogenous administration of insulin to survive. T1DM is often the result of a complex interaction between genes and environmental factors, although there is little evidence that specific environmental factors cause a significant number of cases. Epidemiological and in vivo experimental studies with the aim of studying exposure to environmental chemicals and their roles in the development of T1DM show that multiple factors can intervene, such as the dose and time of exposure, nutritional status and metabolism [8]. Most cases of T1DM occur in children and adolescents [6].
Fig. (2)) The difference between how insulin and cells work in someone without diabetes and people with type 1 and type 2 diabetes mellitus. In type 1 diabetes mellitus, not enough insulin is produced, and in type 2 diabetes mellitus, insulin does not respond efficiently.On the other hand, T2DM, also known as non-insulin dependent diabetes, is the most prevalent type of diabetes in the world. This disease is characterized by the inefficient use of insulin (insulin resistance) and hyperglycemia [9,10]. It has a multifactorial origin, where ethnicity, family background of diabetes, and gestational diabetes are combined with other factors such as advanced age, overweight and obesity, unhealthy diet, physical inactivity, and increased smoking. The symptoms developed by the patient with T2DM can be similar to those of T1DM, though often are less noticeable or absent [7]. This means that T2DM may not be diagnosed until complications arise anddetected years after its onset. Globally, most people with diabetes are affected by T2DM (90% approximately), which generally affect adults almost always, moreover, its prevalence in children is increasing [6].
In the following sections of this chapter, the physiopathology, epidemiology and its impact on the health of obesity and diabetes will be discussed, along with the path from obesity to diabetes, its prevention and therapy.
PHYSIOPATHOLOGY OF OBESITY
In general terms, obesity is produced by an imbalance between the energy ingested and the energy expended. However, today it is known that obesity is a multifactorial disease resulting from the interaction of multiple genetic factors and environmental factors such as sedentary lifestyle and constitution of the diet [11]. The essential difficulty of defining the pathogenesis of obesity lies in need to integrate molecular, genetic, behavioral, developmental, and environmental factors [12] in its definition [13] (Fig. 3).
Fig. (3)) Factors that can influence the chronic positive energy balance, thus subsequently causing obesity.Food consumption stimulates the activation of gastrointestinal signals carried out by mechanical extension, paracrine hormones, nutrients that modulate appetite through various neurotransmitters, intestinal peptides and amino acids. In addition, the autonomous nervous system and several circulating hormones have been implied in the metabolic response to the absorption and metabolism of food and nutrients. This affects appetite, thermogenesis, and fat deposits, among other processes [14]. Studies from the 1990s show that both normal-weight and obese individuals have homeostatic mechanisms that make them resistant to exaggerated weight gain, increasing energy expenditure [15]. However, what has been attempted to elucidate is the importance of each of the factors in what subsequently results in an excessive increase of fat mass.
One of such factors lies on the observation of obesity as a low-grade chronic inflammatory disorder, which is also the trigger of other metabolic disorders [16]. The main characteristic is the increase in the size of white adipose tissue, which is an active element in the regulation of immune and inflammatory processes, among others [17]. About a third of the cells in the adipose tissue are adipocytes, and the others are represented by fibroblasts, endothelial cells, macrophages, stromal cells, immune cells and pre-adipocytes. In thin and healthy people, adipose tissue is constrained to defined deposits, although in the obesity condition, the fat mass increases ectopically [18]. Thus, the hypertrophy of the adipocytes is related to an increase in the infiltration of macrophages [19]. These structures actively participate in the endocrine signals of the adipose tissue, which produces and releases pro and anti-inflammatory factors such as leptin, adiponectin, resistin, cytokines and chymosins such as TNF-α, IL-6 and MCP-1 [20]. This overexpression of cytokines in obesity is what is considered the link between inflammation and obesity.
On the other side, the role of the intestinal microbiota has been extensively studied. It is known that the microbiota of obese people is less diverse than that of non-obese people and specifically, they have an increased proportion of Firmicutes and a decreased proportion of Bacteroidetes [16]. This difference could be directly associated with diet composition. For instance, it is known that subjects who inhabit the United States have a less diverse microbiota than native Venezuelans [21]. The above is reproduced in studies that associate certain characteristics of the diet rich in simple sugars, high in saturated fats and low in fiber or high in probiotics with different types of microbiota. These changes in the composition of diets, can alter the composition of species of the intestinal flora [22].
Susceptibility to obesity is also determined by genetic factors. Since the sequencing of the human genome, several SNP genes (single nucleotide polymorphism) have been associated with obesity. The first of them, FTO (fat mass and obesity-associated gene), has shown that each risk allele is associated with an increase in BMI, weight, waist circumference and adiposity in children and adults [23]. To date, genes for non-syndromic obesity have been associated with both monogenic obesity (e.g. POMC, NPY, LEP, LEPR, MC3R, MC4R, FTO, PCI, and ghrelin receptor) and polygenic obesity (e.g. UCP1, UCP2, UCP3, ADRB1, ADRB2, ADRB3, and SLC6414) [24].
In any case, an obesogenic environment is necessary for its phenotypic expression. The genome-wide association studies (GWAS) found that only about 3% of the BMI variability can be explained by common single nucleotide polymorphisms [25]. Therefore, environmental factors could modulate gene expression, favoring the appearance of obese genotype, establishing that there are critical periods of susceptibility such as pregnancy and early childhood. For example, excessive weight gain during pregnancy and maternal obesity confers greater susceptibility to obesity in adulthood for such offspring [26]. Diet and physical activity can also modulate the expression of certain genes implied in obesity, as well as high amounts of energy, fat, sugars, fried foods, sugary drinks, alcohol and sedentary lifestyle increase the impact of genetic risk [27]. In addition, socioeconomic, behavioral, stress and smoking factors can also modulate heritability conditions and influence genetic predisposition [28].
This makes the pathogenicity of obesity difficult to define since only the interaction of a number of factors is capable of explaining the explosive increase of the prevalence of obesity in the last 40 years.
IMPACT OF OBESITY ON HEALTH
Obesity is a significant risk factor since it is associated with a series of medical conditions that may contribute to increased morbidity and mortality. The link between cardiovascular diseases and diabetes is well known, and hence, the term diabesity, though the implications of obesity are multiple [29]. In addition, obesity is associated with diseases such as osteoarthritis, various types of cancer, kidney and liver disease, sleep apnea, depression, gastroesophageal reflux disease, colorectal polyps, non-alcoholic fatty liver and cirrhosis, among others [30].
Although the growing obesity pandemic has received great attention worldwide, the effects on the morbidity burden remain uncertain. Obesity represents a major health challenge because it substantially increases the risk of diseases, contributing to decreased quality of life. It is also associated with unemployment, social disadvantages, and reduced socioeconomic productivity, thus creating an increased economic burden for the countries. For instance, osteoarthritis, a common consequence of obesity, is one of the leading causes of disability and early retirement [13].
Despite the substantial effects of obesity, weight loss can become a significant reduction in risk for most associated morbidities [31].
Until now, prevention and treatment strategies of obesity both at the individual and population level have not been successful in the long term [13]. Although, at first glance, it is the responsibility of each individual, the behavioral changes (including diet changes and patterns of physical activity) are more likely to occur when supported by social and environmental changes. Such behavioral changes could be inefficient in the absence of support measures in various sectors. Therefore, regulatory actions by governments and greater efforts by companies and civil society are necessary to envision better results [32].
EPIDEMIOLOGY OF OBESITY
Obesity is a global pandemic that affects a billion people worldwide. Estimates from the World Health Organization (WHO) predict that this figure will reach 3.3 billion by 2030 [33].
Between 1980 and 2015, the prevalence of overweight increased by 12.5%. Similarly, the prevalence of obesity increased by 7.5% between the same years and although a decrease in the differences between the sexes was evidenced in recent years, women have a prevalence of obesity greater than men [34]. In 2018, the prevalence of obesity in women was 15%, and 11% in men [35]. Currently, it is estimated that the prevalence of obesity in the world is 30% [36] (Fig. 4).
Fig. (4)) Global prevalence of obesity [36].According to the data provided by the OECD Health at a Glance in 2019 [37], among the OECD countries, the Chilean adult population would have the highest percentage of overweight and obesity, with 74.2%, followed by Mexico (72.5%), United States (71%) and Portugal (67.6%). It is also indicated that 31% of children between 5 and 9 years old who live in OECD countries are overweight. This figure increases to 40% in countries, such as the United States, Italy, New Zealand and Greece.
In Latin America, the prevalence of overweight increased from 45.3% in 1980 to 64.2% in 2015; and obesity increased from 12.9% to 28.3%. On the other hand, in Europe, the prevalence of overweight increased from 48% in 1980 to 59.6% in 2015; and obesity, from 14.5% in 1980 to 22.9% in 2015. Likewise, the prevalence of overweight in South Africa increased from 49.4% in 1980 to 57-8% in 2015, whereas in Ethiopia, it increased from 7.1% in 1980 to 15.9% in 2015 [34].
According to WHO data worldwide, 41 million children between the ages 0 and 5 years are overweight or obese and this figure has increased to 340 million in children aged between 5 and 19 years [38]. An analysis published by LANCET in 2017 shows that in the world, between 1975 and 2016, the average BMI in children increased from 16.8 to 17.2 kg/m2, respectively [39].
In the United States, the cost of treating obesity and its comorbidities was estimated to be 76% higher than the costs of health care for patients with normal BMI [40]. It was also estimated that the cost per person of staying with a high BMI for a lifetime was € 4,209 for men and € 2,445 for women. This was equivalent to 145 billion euros of extra cost for the entire German population at the time of publication of the study [41].
PHYSIOPATHOLOGY OF DIABETES MELLITUS
Diabetes is a complex metabolic disease that involves organ systems and is characterized by chronic hyperglycemia. This is due to a defect in the glycemic regulation due to alterations of the insulin secretion, its action, or both [42]. Insulin is a peptide hormone (Fig. 1) produced by the pancreas; the only one identified capable of eliminating glucose from the blood. Therefore, it has an important role in regulating human metabolism [43, 44]. Insulin acts on the insulin receptor, a membrane-bound tyrosine kinase, which reduces glucose concentrations in the blood by promoting its absorption while suppressing hepatic glucose production [44, 45]. In diabetes, cells are unable to metabolize glucose appropriately due to the inefficient action of insulin on target tissues due to the insensitivity or lack of it [46, 47]. The incapacity of insulin to metabolize glucose occurs when the beta cell of the pancreas produces insufficient insulin or when the organism is unable to use the insulin effectively [44, 48, 49]. This results in insufficient insulin production or the resistance to insulin in the organism, causing a reduced absorption of glucose in the tissues and reduced effect of incretin in the intestine, which results in intracellular hypoglycemia and extracellular hyperglycemia [6]. Intracellular hypoglycemia causes glucogenesis and gluconeogenesis because it leads to fat breakdown, causing diabetic ketoacidosis and decreasing protein synthesis and gamma globulins. This causes cachexia, polyphagia, and poor healing. On the other hand, extracellular hyperglycemia leads to a hyperglycemic coma and osmotic diuresis [50]. More recently, it has been suggested that catecholamines, vitamin D, the renin-angiotensin system, and testosterone may also affect diabetes [42].
IMPACT OF DIABETES MELLITUS ON HEALTH
Long-term elevation of blood glucose levels causes symptoms such as polydipsia, polyuria, polyphagia, blurred vision, and loss of body weight. These are associated with micro and macrovascular complications that lead to dysfunction and failure of various organ systems (cardiovascular, ocular, renal and nervous systems), causing heart disease, stroke, blindness, amputations and kidney disease, Alzheimer’s and some types of cancer, among others. These conditions could cause disability and premature death [8, 48, 51, 52]. The magnitude of the damage caused by hyperglycemia in the organ systems could be related to the time of onset and diagnosis of the pathology [48, 53], taking into account that 1 in 2 adults with diabetes is not diagnosed (232 million people in 2019) [54].
Other findings are related to the “metabolic memory” of the human body, where prolonged periods of exposure to high levels of glucose persistently break down the fibrotic and inflammatory genes in smooth muscle epithelial and vascular cells [55]. In addition, there are epigenetic processes that can contribute to this metabolic memory with evidence that post-translational histones and changes in micro RNA may persist after exposure to high levels of glucose is finished. This suggests a lasting adverse effect of previous hypoglycemia [56]. On the other hand, recent studies evidence a reduction in the quality of life of people with high fasting glucose, impaired glucose tolerance, and T2DM compared to those who do not have it. This is because these people present greater body pain, less physical functioning, sensory deficit, and deterioration of general, mental and vitality health than those without it [30, 57-59].
In this regard, a study noted that the elimination of diabetes as a risk factor for morbidity and mortality extends both general life expectancy and health-adjusted life expectancy for men in 1.3 and 1.4 years and for women in 2.0 and 1.7 years, respectively. In addition, patients with diabetes had a significantly lower health-related quality of life than those without diabetes [7]. However, many of the cases with T2DM could be prevented with lifestyle changes, including maintaining a healthy body weight, consuming a healthy diet, staying physically active, not smoking and drinking alcohol moderately [60].
EPIDEMIOLOGY OF DIABETES MELLITUS
Prevalence and incidence of diabetes worldwide are increasing. It is characterized by being a multifactorial disease that can be attributed in part to the aging of the population, changes in lifestyles linked to greater urbanization, sedentary behavior, and unhealthy eating patterns that have high levels of red meat and processed meat, refined grains and sugary drinks. All this leads to increased obesity [60, 61]. It is estimated that 1in 11 adults has diabetes mellitus (90% has T2DM) (Fig. 5). And Asia is the epicenter of this global epidemic of T2DM [62].
Fig. (5)) Global prevalence of diabetes [62].Globally, the International Diabetes Foundation (IDF) estimated that by 2017 there were 451 million people with diabetes (aged between 18 to 99 years). These numbers are expected to increase to 693 million by 2045. In addition, it is estimated all people (49.7%) who live with diabetes have not been diagnosed. Approximately 5 million deaths worldwide in 2017 were attributable to diabetes in the age range of 20-99 years. Likewise, the world health spending in people with diabetes was US$850 billion in the same year [63].
Regarding the global distribution of diabetes, the highest prevalence of this disease adjusted by age in adults aged 18-99 years was found in the North American and the Caribbean region, with 0.8% (IC 9.1-2.3), whereas the lowest was in the African region, with 4.2% (IC 2.7–7.7%). However, the highest number of people who live with diabetes was found in the Western Pacific region (which hosts countries such as Australia, Japan and China, among others), in this region, there were 168.4 million people with diabetes (IC 149.7–210.9). This shows that this region of the world hosts 37% of the world population with diabetes. Globally, about 79% of people with diabetes live in low and middle-income countries [63]. Among these regions, the countries with the highest number of adults with this pathology are China with 16.4 million people; India, 77 million people; Pakistan with 19.4 million people; Brazil, 16.8 million people; Mexico, 12.8 million people, Indonesia, 10.7 million people, Germany, with 9.5 million: Egypt, 8.9 million and Bangladesh, with 8.4 million people. This trend is expected to continue until 2030. By 2045the number of people with diabetes in Pakistan is expected to exceed that of the United States of America, bringing that country to third place [54].
Regarding sex, the prevalence of diabetes among women aged 18-99 years by 2018 was estimatedat 8.4%, which is lower than in men (8.9%). There were about 12.3 million more men (231.7 million) than women (219.3) living with diabetes. The prevalence of diabetes in both men and women is expected to increase by 2045 [63].
Diabetes affects people in developed and developing countries, which means a significant socioeconomic challenge [64]. The IDF estimates that the global cost of diabetes was US$ 673 billion in 2015, which is projected to increase to US$ 802 billion in 2040. A study estimated that the overall cost of diabetes treatment is US$1,31 billion/year, an estimate that takes into account both direct costs and production loss due to morbidity or premature mortality. In this regard, three out of four people who live with diabetes (352 million) are inactive age (this means between 20 and 64 years of age). This number is expected to increase to 417 million by 2030 and 486 million by 2045. This generates an increasing human impact and will exert strong and increasing pressure on the productivity and economic development of all countries of the world in the coming decades. In addition, health expenditure due to diabetes should be considered. Deaths due to this pathology present a great social, financial, and health system burden. Globally, 11.3% of the deaths are caused by diabetes. Almost half of these deaths occur in people under the age of 60 [54].
FROM OBESITY TO DIABETES
The increased prevalence of T2DM and the prevalence of obesity are closely linked and their extension is mainly attributed to inefficiency and resistance to insulin (Fig. 6) [65]. Obesity causes an increase in the plasmatic levels of free fatty acids (FFA) [66, 67], increasing their cellular uptake and subsequent mitochondrial β-oxidation. This blocks glucose metabolism at a subtracted level of competition [67]. This implies a predominant weight of FFAs at the expense of glucose, decreasing the glucose absorption and glycogen synthesis in the muscle, thus causing a state of chronic, toxic hyperglycemia (glucotoxicity) that further impairs insulin sensitivity [68]. In addition, it increases mitochondrial production of toxic reactive lipids that cause oxidative damage, inflammation, and cellular dysfunction. An accumulation of toxic metabolites within the beta cells of the pancreatic islet decreases insulin production and increases apoptosis of the beta cells, causing an acceleration of the diabetes disease [65, 67]. Hyperglycemia and hyperinsulinemia associated with insulin resistance and glucose intolerance produce glycation of circulating proteins and compounds that leads to advanced glycation and a pathological situation. In addition, the chronic inflammation characteristic of obesity contributes to the pathogeny of diabetes [69, 70]. All of the above leads to a secreting failure of pancreatic and apoptotic beta cells.
Fig. (6)) Mechanisms involved in the path between obesity and diabetes.PREVENTION AND THERAPY
Strategies for preventing, improving, and treating obesity and insulin resistance are associated with reducing fat mass [70]. Lifestyle modifications such as a healthy diet, controlling caloric intake, and increasing physical activity are the first line of treatment, whereas the use of drugs against obesity and bariatric surgery is recommended in cases of need for loss of excessive weight.
There are significant differences between the management of T1DM and T2DM. The latter can be easily prevented and treated, whereas T1DM cannot be prevented with the current knowledge. Diabetes management is complex and requires a multidisciplinary approach, including primary prevention by promoting a healthy diet and a lifestyle with physical activity. In the management of T2DM, diet and physical activity play a fundamental role in achieving the therapeutic in achieving objectives of normoglycemia and normolipidemia. However, not all patients manage to control their diabetic condition with only changes in their diet and lifestyle [71].
The main objective of diabetes treatment is to maintain blood glucose within a normal range. In the long term, a regular and successful treatment decreases the risk that patients develop complications associated with diabetes and is key for the patient to live with the disease. In T1DM, the treatment is a daily and complex task that requires a carefully calculated diet, planned physical activity, multiple daily injections of insulin, and home blood glucose tests a few times a day. In the case of T2DM, treatment includes diet control, exercise, blood glucose analysis, and in some cases, oral medications and/or insulin.
Pharmacological treatment for T2DM was started with the sulphonylurea compounds, which act by stimulating the exocytosis of insulin granules by means of membrane depolarization of beta cells [72]. The effect of these drugs is independent of glucose levels, which increases the risk of hypoglycemia [73]. In addition, sulphonylureas together with other drugs, including metformin, do not prevent the loss of functionality of the beta cells [74]. Incretins are increasingly used in the clinical practice for the treatment of T2DM, since they enhance the dysfunction of beta cells, improving the insulin secretion against a need for glucose and nutrients [75, 76]. Other novel drugs are aimed to target molecules and biochemical pathways involved in the development of insulin resistance, including glucocorticoid receptors inhibitors and factors that reverse and restore stress to the endoplasmic reticulum [70, 77].
Many studies have reported the beneficial effects of physical activity on improving the metabolic profile in obesity and diabetes [78]. Likewise, better glycemic control [79-82], lipid profile [80, 81, 83], cardiovascular fitness [81, 83], antioxidant and inflammatory status [84, 85], quality of life [86], adiposity [82, 87] and aterogenic progression [85] have been shown. The American Diabetes Association (ADA) [88] recommends diet, physical activity, and behavioral therapy so that patients with T2DM with overweight or obesity achieve and maintain weight loss ≥ 5%. Furthermore, even greater weight loss may result in greater benefits in controlling diabetes and cardiovascular risk factors.
CONCLUDING REMARKS
Diabesity significantly affects developed countries and until now, strategies for the prevention and treatment of diabesity both individually and at the population level have not been successful in the long term. Responsibility lies with each individual, though behavioral changes (including changes to a healthier diet and patterns of increased physical activity) are more likely to occur when environmental and social changes support them. However, these behavioral changes could be ineffective given the lack of supporting policies in various sectors. Therefore, regulatory actions by the governments and greater efforts by industry and civil society are necessary for better results. Combating diabesity requires an approach that integrates dietary modifications and regular physical activity and considers new therapeutic options.
CONSENT FOR PUBLICATION
Not Applicable.
CONFLICT OF INTEREST
The author declares no conflict of interest, financial or otherwise.
ACKNOWLEDGEMENT
Authors would like to thanks Vicerrectoria de Investigación y Desarrollo, Universidad de Concepción, to bring support with the text translation.
